A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):86-91.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Angiogenesis Inhibitors
DNA, Neoplasm
Fallopian Tube Neoplasms
Female
Glial Cell Line-Derived Neurotrophic Factor
Humans
Indoles
Middle Aged
Neoplasm Recurrence, Local
Niacinamide
Oligonucleotides
Ovarian Neoplasms
Peritoneal Neoplasms
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A

authors with profiles

WEI HU
ANIL K SOOD